Engineered immune cells take on rare blood disorders
NCT ID NCT07603557
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests a personalized CAR T cell therapy called zolacabtagene autoleucel in 52 adults with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The treatment uses the patient's own immune cells, modified to target and destroy faulty B cells that attack blood cells. The study aims to see if this approach can safely improve blood counts and reduce symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zolacabtagene autoleucel (a CAR T cell therapy made from the patient's own immune cells)
What this could lead to
If it works, this could offer a new treatment option for people with chronic ITP or AIHA who have not responded to other therapies, potentially reducing the need for ongoing medication.
What could go wrong
This is an early phase 2 trial with only 52 participants, so results may not apply to everyone. CAR T cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Local Institution - 101
Boston, Massachusetts, 02114, United States
Contact
-
Local Institution - 102
Seattle, Washington, 98109, United States
Contact
-
Local Institution - 103
Houston, Texas, 77030-2740, United States
Contact
-
Local Institution - 201
Odense, DK-5000, Denmark
Contact
-
Local Institution - 301
Magdeburg, Saxony-Anhalt, 39120, Germany
Contact
-
Local Institution - 302
Erlangen, 91054, Germany
Contact
-
Local Institution - 401
London, Greater London, W12 OHS, United Kingdom
Contact
-
Local Institution - 402
Sheffield, S10 2SJ, United Kingdom
Contact